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414 Postoperative chemotherapy for non–small cell lung cancer: A systematic
review and meta-analysis
Artyom Sedrakyan, MD, PhD, Jan van Der Meulen, PhD, Ken O’Byrne, MD,
Joseph Prendiville, PhD, FRCP, Jennifer Hill, PhD, and Tom Treasure, MD, FRCS, London,
United Kingdom, and Dublin, Ireland
We performed a systematic review of randomized trials of postoperative chemotherapy. We
found 11% relative reduction in mortality for cisplatin (95% CI, 4%-18%) and 17% for uracil
plus ftorafur (95% CI, 5%-27%) compared with that after surgical intervention alone. Selected
patients with resected NSCLC should be offered chemotherapy.
420 Sleeve segmentectomy for non–small cell lung carcinoma
Morihito Okada, MD, PhD, Wataru Nishio, MD, PhD, Toshihiko Sakamoto, MD, PhD,
Kazuya Uchino, MD, Tsuyoshi Yuki, MD, Akio Nakagawa, MD, and Noriaki Tsubota, MD,
PhD, Akashi City, Hyogo, Japan
We carried out sleeve segmentectomy for small-sized hilar non–small cell lung cancers in 16
patients. Bronchial reconstruction was successful in all patients, with neither bronchial
complications nor local recurrences. This atypical type of bronchoplasty should be considered,
even for patients with noncompromised function, because of its safety and usefulness.
Surgery for Acquired
Cardiovascular Disease
(ACD)
425 Clopidogrel and bleeding in patients undergoing elective coronary artery
bypass grafting
LiQian Chen, MD, PhD, Arthur W. Bracey, MD, Rajko Radovancevic, MD, John R. Cooper, Jr,
MD, Charles D. Collard, MD, William K. Vaughn, PhD, and Nancy A. Nussmeier, MD,
Houston, Tex
We studied coagulation profiles, including platelet function tests, at prespecified intervals in 45
clopidogrel recipients and 45 control subjects. Prebypass platelet function predicted bleeding.
Despite a strict transfusion algorithm, clopidogrel recipients required greater transfusions of
platelets and red blood cells. Postbypass platelet transfusion to an adenosine diphosphate
aggregation response of greater than 40% might decrease transfusions.
432 Clopidogrel did not inhibit platelet function early after coronary bypass
surgery: A prospective randomized trial
Eric Lim, MRCS, Jacqueline Cornelissen, MPhil, Tom Routledge, MRCS, Stephen Kirtland,
PhD, Susan C. Charman, MSc, Sarah Bellm, BSc, Helen Munday, RGN, Omar Khan, MRCS,
Imran Masood, MRCS, and Stephen Large, FRCS, Cambridge, United Kingdom
We compared efficacy between aspirin and clopidogrel with light aggregometry in a
prospective randomized trial. Interim data revealed that clopidogrel, unlike aspirin, did not
inhibit platelet aggregation on postoperative day 5 and therefore should not be used as a sole
antiplatelet agent early after coronary surgery.
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